Published 11 days ago

Novel Agent Curbs Alzheimer's-Related Agitation

Summary by Medscape

AXS-05, a combination of dextromethorphan and bupropion, led to a rapid and sustained improvement in agitation related to Alzheimer's disease in the phase 3 ACCORD trial. Medscape Medical News

0 Articles

All

Left

Center

Right

Medscape

Novel Agent Curbs Alzheimer's-Related Agitation

AXS-05, a combination of dextromethorphan and bupropion, led to a rapid and sustained improvement in agitation related to Alzheimer's disease in the phase 3 ACCORD trial. Medscape Medical News

11 days ago·United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.